These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

210 related items for PubMed ID: 38166846

  • 1. The residual cancer burden index as a valid prognostic indicator in breast cancer after neoadjuvant chemotherapy.
    Xu X, Zhao W, Liu C, Gao Y, Chen D, Wu M, Li C, Wang X, Song X, Yu J, Liu Z, Yu Z.
    BMC Cancer; 2024 Jan 02; 24(1):13. PubMed ID: 38166846
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Time to surgery following neoadjuvant chemotherapy for breast cancer impacts residual cancer burden, recurrence, and survival.
    Sutton TL, Schlitt A, Gardiner SK, Johnson N, Garreau JR.
    J Surg Oncol; 2020 Dec 02; 122(8):1761-1769. PubMed ID: 33125715
    [Abstract] [Full Text] [Related]

  • 7. Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers.
    Lee HJ, Park IA, Song IH, Kim SB, Jung KH, Ahn JH, Ahn SH, Kim HH, Gong G.
    PLoS One; 2015 Dec 02; 10(9):e0137885. PubMed ID: 26394326
    [Abstract] [Full Text] [Related]

  • 8. Prediction of survival after neoadjuvant chemotherapy for breast cancer by evaluation of tumor-infiltrating lymphocytes and residual cancer burden.
    Asano Y, Kashiwagi S, Goto W, Takada K, Takahashi K, Hatano T, Noda S, Takashima T, Onoda N, Tomita S, Motomura H, Ohsawa M, Hirakawa K, Ohira M.
    BMC Cancer; 2017 Dec 28; 17(1):888. PubMed ID: 29282021
    [Abstract] [Full Text] [Related]

  • 9. Prognostic value of the Residual Cancer Burden index according to breast cancer subtype: Validation on a cohort of BC patients treated by neoadjuvant chemotherapy.
    Hamy AS, Darrigues L, Laas E, De Croze D, Topciu L, Lam GT, Evrevin C, Rozette S, Laot L, Lerebours F, Pierga JY, Osdoit M, Faron M, Feron JG, Laé M, Reyal F.
    PLoS One; 2020 Dec 28; 15(6):e0234191. PubMed ID: 32579551
    [Abstract] [Full Text] [Related]

  • 10. Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer.
    Miglietta F, Dieci MV, Tsvetkova V, Griguolo G, Vernaci G, Menichetti A, Faggioni G, Giarratano T, Mioranza E, Genovesi E, Cumerlato E, Bottosso M, Saibene T, Michieletto S, Lo Mele M, Conte P, Guarneri V.
    Oncologist; 2020 Sep 28; 25(9):e1355-e1362. PubMed ID: 32618068
    [Abstract] [Full Text] [Related]

  • 11. Residual Cancer Burden Class Associated with Survival Outcomes in Women with Different Phenotypic Subtypes of Breast Cancer After Neoadjuvant Chemotherapy.
    Elder EA, Livasy CA, Donahue EE, Neelands B, Patrick A, Needham M, Sarantou T, Hadzikadic-Gusic L, Heeke AL, White RL.
    Ann Surg Oncol; 2022 Dec 28; 29(13):8060-8069. PubMed ID: 35980548
    [Abstract] [Full Text] [Related]

  • 12. Validation of Residual Cancer Burden as Prognostic Factor for Breast Cancer Patients After Neoadjuvant Therapy.
    Müller HD, Posch F, Suppan C, Bargfrieder U, Gumpoldsberger M, Hammer R, Hauser H, Dandachi N, Prein K, Stoeger H, Lax S, Balic M.
    Ann Surg Oncol; 2019 Dec 28; 26(13):4274-4283. PubMed ID: 31452052
    [Abstract] [Full Text] [Related]

  • 13. Comparison of Breast Cancer Staging Systems After Neoadjuvant Chemotherapy.
    Kantor O, Laws A, Pastorello RG, King C, Wong S, Dey T, Schnitt S, King TA, Mittendorf EA.
    Ann Surg Oncol; 2021 Nov 28; 28(12):7347-7355. PubMed ID: 33956276
    [Abstract] [Full Text] [Related]

  • 14. Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    Campbell JI, Yau C, Krass P, Moore D, Carey LA, Au A, Chhieng D, Giri D, Livasy C, Mies C, Rabban J, Sarode VR, Singh B, Esserman L, Chen YY.
    Breast Cancer Res Treat; 2017 Aug 28; 165(1):181-191. PubMed ID: 28577078
    [Abstract] [Full Text] [Related]

  • 15. Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.
    Pinard C, Debled M, Ben Rejeb H, Velasco V, Tunon de Lara C, Hoppe S, Richard E, Brouste V, Bonnefoi H, MacGrogan G.
    Breast Cancer Res Treat; 2020 Jan 28; 179(1):11-23. PubMed ID: 31529299
    [Abstract] [Full Text] [Related]

  • 16. Prognostic value of residual cancer burden and Miller-Payne system after neoadjuvant chemotherapy for breast cancer.
    Wang W, Liu Y, Zhang H, Zhang S, Duan X, Ye J, Xu L, Zhao J, Cheng Y, Liu Q.
    Gland Surg; 2021 Dec 28; 10(12):3211-3221. PubMed ID: 35070881
    [Abstract] [Full Text] [Related]

  • 17. MRI Radiomics for Assessment of Molecular Subtype, Pathological Complete Response, and Residual Cancer Burden in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy.
    Choudhery S, Gomez-Cardona D, Favazza CP, Hoskin TL, Haddad TC, Goetz MP, Boughey JC.
    Acad Radiol; 2022 Jan 28; 29 Suppl 1(Suppl 1):S145-S154. PubMed ID: 33160859
    [Abstract] [Full Text] [Related]

  • 18. Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
    Steenbruggen TG, van Seijen M, Janssen LM, van Ramshorst MS, van Werkhoven E, Vrancken Peeters MTDF, Wesseling J, Lips EH, Sonke GS.
    Clin Cancer Res; 2019 Aug 15; 25(16):4985-4992. PubMed ID: 31076546
    [Abstract] [Full Text] [Related]

  • 19. Does Residual Cancer Burden Predict Local Recurrence After Neoadjuvant Chemotherapy?
    Pestana CV, Livasy CA, Donahue EE, Neelands B, Tan AR, Sarantou T, Hadzikadic-Gusic L, White RL.
    Ann Surg Oncol; 2022 Nov 15; 29(12):7716-7724. PubMed ID: 35810226
    [Abstract] [Full Text] [Related]

  • 20. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
    Karatas F, Erdem GU, Sahin S, Aytekin A, Yuce D, Sever AR, Babacan T, Ates O, Ozisik Y, Altundag K.
    Breast; 2017 Apr 15; 32():237-244. PubMed ID: 27318645
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.